tiprankstipranks
Trending News
More News >
Community Health (DE:CG5)
FRANKFURT:CG5
Germany Market

Community Health (CG5) Earnings Dates, Call Summary & Reports

Compare
1 Followers

Earnings Data

Report Date
Apr 29, 2026
After Close (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
-0.07
Last Year’s EPS
-0.03
Same Quarter Last Year
Based on 7 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 18, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call communicates meaningful operational and financial progress — sequential margin expansion, improved cash flow and a clear deleveraging path supported by divestiture proceeds and targeted cost controls — along with ongoing strategic investments and technology/AI initiatives. However, there are notable near-term headwinds: modest volume softness, the revenue impact of multiple divestitures, exposure to lower ACA exchange enrollment (modeled as a $20M–$30M EBITDA headwind), rising medical specialist fees (5%–8% expected), and a ~$140M cash flow drag from an extra payroll period in 2026. On balance, the company has demonstrated positive momentum on margins, cash generation and balance-sheet repair while acknowledging manageable operational and market risks that have been incorporated into conservative 2026 guidance.
Company Guidance
CHS’s initial 2026 guidance calls for net revenue of $11.6–$12.0 billion, adjusted EBITDA of $1.34–$1.49 billion, cash flows from operations of $600–$700 million and capital expenditures of $350–$400 million; the company says this reflects roughly 4% core same‑site growth (after an estimated $20–$30 million EBITDA headwind from reduced HICS/enrollment), starts from a 2025 EBITDA baseline of about $1.36 billion, and excludes potential state‑directed payment and rural transformation benefits. The bridge subtracts divestiture impacts (about $30–$40 million of EBITDA from 2025‑completed sales and roughly $80–$90 million from the 2026 class; ~$210–$230 million of 2025 net revenue from early 2025 divestitures and ~ $1.0 billion net revenue reduction from 2026 announced/expected sales), and incorporates a ~$140 million 2026 cash headwind from an extra payroll period; Q4 2025 adjusted EBITDA was $395 million (12.7% margin), Q4 same‑store net revenue +2.1% and net revenue per adjusted admission +2.4%, Q4 medical specialist fees $169 million (5.4% of revenue, expected to grow 5–8% in 2026), FY25 cash flow from operations $543 million ($712 million adjusted excluding divestiture taxes) with adjusted free cash flow $150 million, year‑end 2025 leverage 6.6x (net debt $10.1 billion, expected to fall to ~ $9.2 billion after Huntsville), and no ABL draws with next major maturity in 2029.
Same-Store Revenue and Pricing Momentum
Same-store net revenue for Q4 increased 2.1% year-over-year, driven by a 2.4% increase in net revenue per adjusted admission.
Adjusted EBITDA and Margin Expansion
Q4 adjusted EBITDA was $395 million with a 12.7% margin; adjusted EBITDA was slightly up versus Q4 2024 on a same-store basis and the company achieved the midpoint of updated FY2025 guidance.
Improved Cash Flow and Free Cash Flow Positive
Cash flows from operations were $266 million in Q4 and $543 million for FY2025 (vs. $480 million in 2024). Excluding cash taxes on divestiture gains, adjusted cash flows from operations were $712 million and adjusted free cash flow was $150 million.
Leverage and Balance Sheet Progress
Net leverage improved from 7.4x at year-end 2024 to 6.6x at year-end 2025 and has been further reduced through early 2026 note redemptions; expected net debt after the Huntsville divestiture is ~ $9.2 billion (down from $10.1B YE2025 and $11.4B YE2024).
Material Divestiture Proceeds and Debt Reduction
Completed and pending divestitures generated significant cash (e.g., Clarksville ~ $623M gross, outreach labs ~$152M, contingent $91M) used to redeem high-coupon notes (two $223M redemptions at 103%) and reduce leverage.
Operational & Cost Control Improvements
Sequential adjusted EBITDA margin expansion, controlled labor (average hourly wage growth within expectations and flat contract labor), and 'live' expense down 110 bps YoY to 14.4% of net revenue in Q4 (down 50 bps for FY2025).
Strategic Investments and Service-Line Growth
Targeted market investments produced local wins: ER visits +13% in Knoxville over 2 years after ER expansion; Grandview births +20% (4,000+ babies) after $10M women's services investment; cardiac surgeries +16% in Longview; inbound transfers +~35% in Carlsbad.
Technology Transformation and Early AI Adoption
ERP implementation completed and reportedly saved ~ $50 million in the first year; AI use cases deployed or in rollout include appeals/autonomous coding, virtual patient sitters (reducing safety events), ambient documentation tools, and maternal-fetal early warning systems.

Community Health (DE:CG5) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

DE:CG5 Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 29, 2026
2026 (Q1)
-0.07 / -
-0.025
Feb 18, 2026
2025 (Q4)
-0.04 / >-0.01
-0.35697.62% (+0.35)
Oct 23, 2025
2025 (Q3)
-0.21 / 1.08
-0.255523.33% (+1.33)
Jul 23, 2025
2025 (Q2)
-0.09 / -0.04
-0.14470.59% (+0.10)
Apr 23, 2025
2025 (Q1)
-0.07 / -0.03
-0.11978.57% (+0.09)
Feb 18, 2025
2024 (Q4)
0.07 / -0.36
-0.348-2.44% (>-0.01)
Oct 23, 2024
2024 (Q3)
-0.18 / -0.25
-0.289.09% (+0.03)
Jul 24, 2024
2024 (Q2)
-0.12 / -0.14
-0.18722.73% (+0.04)
Apr 24, 2024
2024 (Q1)
-0.14 / -0.12
-0.36567.44% (+0.25)
Feb 20, 2024
2023 (Q4)
0.04 / -0.35
1.273-127.33% (-1.62)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DE:CG5 Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 18, 2026
€2.82€2.96+4.96%
Oct 23, 2025
€2.78€3.50+25.90%
Jul 23, 2025
€3.26€2.58-20.86%
Apr 23, 2025
€2.10€2.34+11.43%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Community Health (DE:CG5) report earnings?
Community Health (DE:CG5) is schdueled to report earning on Apr 29, 2026, After Close (Confirmed).
    What is Community Health (DE:CG5) earnings time?
    Community Health (DE:CG5) earnings time is at Apr 29, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Community Health stock?
          The P/E ratio of Community Health is N/A.
            What is DE:CG5 EPS forecast?
            DE:CG5 EPS forecast for the fiscal quarter 2026 (Q1) is -0.07.

              Community Health (DE:CG5) Earnings News

              CYH Surges on Q4 Beat
              Premium
              Market News
              CYH Surges on Q4 Beat
              3y ago